We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current KNBIF market cap is 11.84M. The company's latest EPS is CAD -0.0400 and P/E is -3.25.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 1.69M | 1.34M | 1.61M | 2.67M | 2.82M |
| Operating Income | -3.59M | -4.23M | -4.88M | -3.36M | -4.09M |
| Net Income | -960k | -3.98M | -4.61M | -3.89M | -5.27M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 2.76M | 5.04M | 6.13M | 5.62M | 5.68M |
| Total Liabilities | 1.92M | 3.96M | 7.7M | 9.76M | 14.09M |
| Total Equity | 837k | 1.07M | -1.57M | -4.14M | -8.41M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -955k | -3.94M | -2.29M | -3.04M | -2.08M |
| Investing | -97k | -166k | -374k | -108k | -115k |
| Financing | 1.81M | 4.28M | 2.81M | 3.1M | 2.98M |
| Market Cap | 11.84M |
| Price to Earnings Ratio | -3.25 |
| Price to Sales Ratio | 6.07 |
| Price to Cash Ratio | 22.81 |
| Price to Book Ratio | -2.04 |
| Dividend Yield | - |
| Shares Outstanding | 131.84M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 22.36k |
| 52 Week Change | 8.19% |
| 52 Week High | 0.12277 |
| 52 Week Low | 0.042 |
| Spread (Intraday) | 100.11 (100%) |
| Company Name | Kane Biotech Inc (QB) |
| Address |
290-100 innovation drive winnipeg, manitoba R3T 6G2 |
| Website | https://www.kanebiotech.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
